Dr. Pacold is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
560 1st Ave
New York, NY 10016Phone+1 212-731-5003Fax+1 212-731-5517
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2008 - 2012
Massachusetts General HospitalInternship, Internal Medicine, 2006 - 2007
Harvard Medical SchoolClass of 2006
Certifications & Licensure
NY State Medical License 2016 - 2026
MA State Medical License 2008 - 2025- American Board of Radiology Radiation Oncology
Publications & Presentations
PubMed
- 240 citationsTherapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor†Sang Min Lim, Kenneth D. Westover, Scott B. Ficarro, Rane A. Harrison, Hwan Geun Choi
Angewandte Chemie. 2014-01-03 - 354 citationsA PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fateMichael E. Pacold, Kyle R. Brimacombe, Sze Ham Chan, Jason M. Rohde, Caroline A. Lewis
Nature Chemical Biology. 2016-06-01 - 133 citationsNeurons Release Serine to Support mRNA Translation in Pancreatic Cancer.Robert S. Banh, Douglas E. Biancur, Keisuke Yamamoto, Albert S. W. Sohn, Beth Walters
Cell. 2020-11-25
Journal Articles
- SFXN1 Is a Mitochondrial Serine Transporter Required for One-Carbon MetabolismMichael E Pacold, Science Magazine
Press Mentions
- Nerves Keep Pancreatic Cancer Cells from StarvingNovember 2nd, 2020
Immunological & Molecular Clues Reveal New Insights to Pancreatic CancerAugust 2nd, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
